REMEGEN(09995.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 4.66 billion, turned profitable from a loss YoY
August 24, 2026, REMEGEN(09995.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 5.85 billion, increased by 435.74% YoY; Net Profit stood at CNY 4.66 billion, turned profitable from a loss YoY; Profit Attributable to Shareholders stood at CNY 4.66 billion, turned profitable from a loss YoY; Basic Earnings Per Share (EPS) stood at CNY 8.32.
In terms of profitability, REMEGEN Gross Profit changed from CNY 921.85 million in the same period last year to CNY 5.58 billion in the current period, increased by CNY 4.66 billion; gross profit margin changed from 84.42% in the same period last year to 95.4% in the current period, increased by 10.98 percentage points; net profit changed from loss of CNY 449.57 million in the same period last year to CNY 4.66 billion in the current period, increased by CNY 5.11 billion; net profit margin changed from -41.17% in the same period last year to 79.69% in the current period, increased by 120.86 percentage points.
In terms of earnings quality, REMEGEN Operating Profit changed from loss of CNY 407.76 million in the same period last year to CNY 4.68 billion in the current period, increased by CNY 5.09 billion; Operating Profit Margin changed from -37.34% in the same period last year to 80.01% in the current period, increased by 117.35 percentage points.
In terms of financial soundness, REMEGEN Debt-to-Asset Ratio changed from 59.7% in the same period last year to 15.57% in the current period, decreased by 44.13 percentage points; Total Equity changed from CNY 2.357 billion in the same period last year to CNY 8.314 billion in the current period, increased by CNY 5.96 billion; Current Liabilities changed from CNY 2.56 billion in the same period last year to CNY 1.37 billion in the current period, decreased by CNY 1.19 billion; Quick Ratio changed from 0.8 in the same period last year to 4.27 in the current period, increased by 3.47 percentage points.
In terms of R&D investment focus, REMEGEN R&D Expenses changed from CNY 647.22 million in the same period last year to CNY 414.15 million in the current period, decreased by CNY 233.07 million; R&D to Total Revenue Ratio changed from 59.27% in the same period last year to 7.08% in the current period, decreased by 52.19 percentage points.
By the close of trading on August 24, 2026, REMEGEN(09995) saw a loss of 5.96% in its share price, closing at HKD 74.2. The full-day turnover stood at HKD 287.25 million, with the latest market capitalization at HKD 15.48 billion.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
